William Silbey - UCB SA Exec Counsel
| UCBJF Stock | USD 68.91 6.39 0.00% |
Insider
William Silbey is Exec Counsel of UCB SA
| Age | 64 |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.UCB SA has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Zara Gaudioso | Ocugen Inc | N/A | |
| Lisa Middlebrook | Ibio Inc | N/A | |
| Fangyong Du | Adagene | 54 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Frdrique Menzaghi | Cara Therapeutic | 58 | |
| Melissa Berquist | Ibio Inc | N/A | |
| Allan MD | Foghorn Therapeutics | 49 | |
| Merdad Parsey | Arcus Biosciences | 58 | |
| Tiffany MBA | Ocugen Inc | N/A | |
| Dr DSc | Cara Therapeutic | 60 | |
| Gerald Md | Foghorn Therapeutics | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| Christopher Garcia | Arcus Biosciences | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Vijay Tammara | Ocugen Inc | 64 | |
| Mike Jenkins | Ibio Inc | N/A | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandrine CFA, Ex CFO | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| William Silbey, Exec Counsel | ||
| Pr LowFriedrich, Chief VP | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Caroline Vancoillie, Chief Functions | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 17.07 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.62 X | |||
| Price To Book | 1.52 X |
Currently Active Assets on Macroaxis
Other Information on Investing in UCB Pink Sheet
UCB SA financial ratios help investors to determine whether UCB Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UCB with respect to the benefits of owning UCB SA security.